Lehrstuhl für Geburtshilfe und Frauenheilkunde

Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020) (2021) Burghaus S, Schäfer SD, Beckmann M, Brandes I, Brünahl C, Chvatal R, Drahoå ovský J, et al. Journal article Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium (2021) Morra A, Jung AY, Behrens S, Keeman R, Ahearn TU, Anton-Culver H, Arndt V, et al. Journal article Cell-based endometrial regeneration: current status and future perspectives (2021) Keyhanvar N, Zarghami N, Bleisinger N, Hajipour H, Fattahi A, Nouri M, Dittrich R Journal article, Review article Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk (2021) Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, et al. Journal article NGS zur Selektion innovativer Therapien – Was bringt das? (2021) Schulmeyer C, Bader S, Hübner H, Rübner M, Fasching P Journal article, Review article Germline BRCA1/2 mutations and severe haematological toxicities in patients with breast cancer treated with neoadjuvant chemotherapy (2021) Furlanetto J, Möbus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Lübbe K, et al. Journal article An update on platelet-rich plasma (PRP) therapy in endometrium and ovary related infertilities: clinical and molecular aspects (2021) Hajipour H, Farzadi L, Latifi Z, Keyhanvar N, Navali N, Fattahi A, Nouri M, Dittrich R Journal article, Review article Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women (2021) Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, Wahlstrom C, Pooley KA, et al. Journal article Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany (2021) Lux MP, Brendle-Behnisch A, Hack C, Preuss C, Arkudas A, Horch RE, Beckmann M, Jud S Journal article Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane (2021) O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, et al. Conference contribution